HEPATIC STEATOSIS AS DIABETES TYPE 2 PREDICTOR

被引:9
|
作者
Loureiro, Carolina [1 ]
Martinez-Aguayo, Alejandro [1 ]
Campino, Carmen [2 ]
Carvajal, Cristian [2 ]
Fardella, Carlos [2 ]
Garcia, Hernan [1 ]
机构
[1] Pontificia Univ Catolica Chile, Div Pediat, Unidad Endocrinol Pediat, Santiago 8330074, Chile
[2] Pontificia Univ Catolica Chile, Dept Endocrinol, Santiago 8330074, Chile
关键词
Non alcoholic fatty liver disease (NAFLD); Steatohepatitis; Alanine aminotransferase; Insulin resistance; Type; 2; diabetes; FATTY LIVER-DISEASE; INSULIN-RESISTANCE; ALANINE AMINOTRANSFERASE; OBESE ADOLESCENTS; ADIPOSE-TISSUE; CHILDREN; ADIPONECTIN; PREVALENCE; INTERLEUKIN-6; OVERWEIGHT;
D O I
10.3305/nh.2014.29.2.7098
中图分类号
R15 [营养卫生、食品卫生]; TS201 [基础科学];
学科分类号
100403 ;
摘要
Non alcoholic fatty liver disease (NAFLD) is associated with obesity, insulin resistance (IR) and increased type 2 diabetes (T2D). Alanine aminotransferase (ALT) is recognized as biochemical marker of NAFLD, currently used as screening for this disease. Objective: To estimate the associations between (ALT) with anthropometric variables, insulin resistance and inflamatory markers in pediatric population. Patients and Method: we studied 348 subjects (52.7% females), aged between 4.9 and 15.6 years. Blood samples for measuring: AST, ALT, glycaemia, insulin, lipid profile, hsCRP TNF-alpha, IL-6 and adiponectin. We calculate HOMA-IR, QUICKI y el HOMA-beta. The results are expressed are expressed as median interquartile range. Variables were log10 transformed before Pearson correlations analyze. Results: Serum ALT levels were positively associated with BMI-SDS (r = 0.335), waist/height ratio (r = 0.358), insulin (r = 0.33), HOMA-IR (r = 0.33), HOMA-beta (r = 0.26), TG/HDL-c (r = 0.2), hsCRP (r = 0.3); and a negative association with QUICKI (r = -0.25) and adiponectin (r = -0.113). Non-association with ALT, glycaemia, TNF-a and IL-6 was found. Conclusion: Our study demonstrated that ALT, but not AST, was significantly correlated with of insulin resistance and inflamatory markers, all of them recognized as risk parameters of pre diabetes stage. ALT should be part of the evaluation of all obesity children, mainly those with other cardiometabolic risk factors, since it could predict later development of T2DM. Further imaging studies are necessary to confirm fatty liver disease in this population.
引用
收藏
页码:350 / 358
页数:9
相关论文
共 50 条
  • [41] Triple therapy with pioglitazone/exenatide/metformin prevents hepatic fibrosis and steatosis in type 2 diabetes
    Lavrynenko, O.
    Abdul-Ghani, M.
    Alatrach, M.
    Puckett, C.
    Adams, J.
    Cersosimo, E.
    Alkhouri, N.
    DeFronzo, R. A.
    DIABETOLOGIA, 2020, 63 (SUPPL 1) : S66 - S67
  • [42] Interest of hepatic steatosis index (HSI) in screening for metabolic steatopathy in patients with type 2 diabetes
    Fennoun, Halima
    El Mansouri, Souhaila
    Tahiri, Mohammed
    Haraj, Nassim Essabah
    El Aziz, Siham
    Hadad, Fouad
    Hliwa, Wafaa
    Badr, Wafaa
    Chadli, Asma
    PAN AFRICAN MEDICAL JOURNAL, 2020, 37 : 270
  • [43] Hepatic Steatosis and Fibrosis in Type 2 Diabetes: A Risk-Based Approach to Targeted Screening
    Poustchi, Hossein
    Alaei-Shahmiri, Fariba
    Aghili, Rokhsareh
    Nobarani, Sohrab
    Malek, Mojtaba
    Khamseh, Mohammad E.
    ARCHIVES OF IRANIAN MEDICINE, 2021, 24 (03) : 177 - 186
  • [44] Hepatic Fibrosis but Not Steatosis Is Associated with Diabetic Kidney Disease in Nonobese Patients with Type 2 Diabetes
    Seo, Da Hea
    Cho, Yongin
    Ahn, Seong Hee
    Hong, Seongbin
    Lee, Yong-Ho
    Choi, Youngju
    Huh, Byoung Wook
    Huh, Kap Bum
    Kim, So Hun
    DIABETES, 2020, 69
  • [45] Evaluation of Hepatic Steatosis and Adiposity in People with Type 1 Diabetes and Obesity
    Trikudanathan, Subbulaxmi
    Amin, Kathan
    Bambha, Kiran
    Melhorn, Susan J.
    Sekhon, Mandeep
    Navarro, Sandi
    Schur, Ellen A.
    Hirsch, Irl B.
    DIABETES, 2024, 73
  • [46] Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes
    Petersen, KF
    Dufour, S
    Befroy, D
    Lehrke, M
    Hendler, RE
    Shulman, GI
    DIABETES, 2005, 54 (03) : 603 - 608
  • [47] Prevalence of and Risk Factors for Hepatic Steatosis and Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: The Edinburgh Type 2 Diabetes Study
    Williamson, Rachel M.
    Price, Jacqueline F.
    Glancy, Stephen
    Butcher, Isabella
    Perry, Elisa
    Nee, Lisa D.
    Hayes, Peter C.
    Frier, Brian M.
    Van Look, Liesbeth A. F.
    Johnston, Geoffrey I.
    Reynolds, Rebecca M.
    Strachan, Mark W. J.
    DIABETES, 2009, 58 : A271 - A271
  • [48] Association of the Sizes and Composition of HDL with Hepatic Steatosis in Adolescents with Type 2 Diabetes (T2D)
    Orozco Morales, Jose Antonio
    Torres Tamayo, Margarita
    Medina Urrutia, Aida
    Juarez Rojas, Juan Gabriel
    Reyes Barrera, Juan
    Jorge Galarza, Esteban
    Dies Suarez, Pilar
    Medina Bravo, Patricia
    HORMONE RESEARCH IN PAEDIATRICS, 2018, 90 : 229 - 229
  • [49] Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)
    Saenz, Enrique Valdez
    Leiva, Eddison Godinez
    Lomonaco, Romina
    Kalavalapalli, Srilaxmi
    Marangi, Stephen A.
    Gonzalez, Maria A.
    Rocha, Andrea Ortiz
    Chi, Xiaofei
    Gurka, Matthew J.
    Barb, Diana
    Sharma, Anu
    Cusi, Kenneth
    DIABETES, 2023, 72
  • [50] A new predictor for type 2 diabetes?
    Sorisky, Alexander
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2008, 178 (03) : 313 - 315